Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Interleukin-10 Protection against Lipopolysaccharide-Induced Neuro-Inflammation and Neurotoxicity in Ventral Mesencephalic Cultures.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Zhu Y;Zhu Y;Zhu Y; Chen X; Chen X; Liu Z; Liu Z; Peng YP; Peng YP; Qiu YH; Qiu YH
  • المصدر:
    International journal of molecular sciences [Int J Mol Sci] 2015 Dec 28; Vol. 17 (1). Date of Electronic Publication: 2015 Dec 28.
  • نوع النشر :
    Journal Article; Research Support, Non-U.S. Gov't
  • اللغة:
    English
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
      Inflammation/*chemically induced ; Interleukin-10/*pharmacology ; Lipopolysaccharides/*adverse effects ; Mesencephalon/*metabolism ; Neurotoxicity Syndromes/*etiology ; Parkinson Disease/*etiology; Animals ; Anti-Inflammatory Agents/pharmacology ; Astrocytes/immunology ; Astrocytes/metabolism ; Coculture Techniques ; Inflammation/immunology ; Mesencephalon/immunology ; Microglia/immunology ; Microglia/metabolism ; Neurons/immunology ; Neurons/metabolism ; Neurotoxicity Syndromes/immunology ; Neurotoxicity Syndromes/metabolism ; Parkinson Disease/immunology ; Parkinson Disease/metabolism ; Rats ; Rats, Sprague-Dawley
    • نبذة مختصرة :
      Interleukin (IL)-10, an anti-inflammatory cytokine, is expressed in the brain and can inhibit microglial activation. Herein, we utilized lipopolysaccharide (LPS)-induced inflammatory Parkinson's disease (PD) cell model to determine whether microglia and astrocytes are necessary targets for IL-10 neuroprotection. Primary ventral mesencephalic (VM) cultures with different composition of neurons, microglia and astrocytes were prepared. The cells were exposed to IL-10 (15, 50 or 150 ng/mL) 1 h prior to LPS (50 ng/mL) treatment. LPS induced dopaminergic and non-dopaminergic neuronal loss in VM cultures, VM neuron-enriched cultures, and neuron-microglia co-cultures, but not in neuron-astrocyte co-cultures. IL-10 reduced LPS-induced neuronal loss particularly in single VM neuron cultures. Pro-inflammatory mediators (TNF-α, IL-1β, inducible nitric oxide synthase and cyclooxygenase-2) were upregulated in both neuron-microglia and neuron-astrocyte co-cultures by LPS. In contrast, neurotrophic factors (brain-derived neurotrophic factor, insulin-like growth factor-1 or glial cell-derived neurotrophic factor) were downregulated in neuron-microglia co-cultures, but upregulated in neuron-astrocyte co-cultures by LPS. IL-10 reduced both the increase in production of the pro-inflammatory mediators and the decrease in production of the neurotrophic factors induced by LPS. These results suggest that astrocytes can balance LPS neurotoxicity by releasing more neurotrophic factors and that IL-10 exerts neuroprotective property by an extensive action including direct on neurons and indirect via inhibiting microglial activation.
    • References:
      Mov Disord. 2002 Jan;17(1):116-24. (PMID: 11835448)
      Int Immunopharmacol. 2014 Jun;20(2):298-306. (PMID: 24735815)
      Mediators Inflamm. 2013;2013:480739. (PMID: 23997430)
      Clin Neurosci Res. 2006 Dec 6;6(5):261-281. (PMID: 18060039)
      J Immunol. 1993 Oct 15;151(8):4258-65. (PMID: 8409400)
      Cytokine. 2014 Jul;68(1):40-9. (PMID: 24656930)
      Neurobiol Learn Mem. 2014 Dec;116:117-31. (PMID: 25444719)
      Int J Mol Sci. 2012;13(5):5324-37. (PMID: 22754299)
      Science. 2001 Jul 20;293(5529):493-8. (PMID: 11408619)
      Mol Ther. 2008 Aug;16(8):1392-9. (PMID: 18545225)
      FASEB J. 2004 Oct;18(13):1618-20. (PMID: 15319363)
      J Pharmacol Exp Ther. 2003 Jan;304(1):1-7. (PMID: 12490568)
      J Immunol. 2000 Jun 1;164(11):5564-74. (PMID: 10820230)
      ISRN Neurol. 2011;2011:476158. (PMID: 22389821)
      J Neurosci. 2002 Apr 1;22(7):2478-86. (PMID: 11923412)
      Brain Res. 2011 Feb 10;1373:189-94. (PMID: 21138740)
      Brain Pathol. 2014 Nov;24(6):584-98. (PMID: 24593806)
      Neuroscience. 2002;110(1):49-58. (PMID: 11882372)
      Parkinsonism Relat Disord. 2002 Jun;8(5):329-41. (PMID: 15177062)
      Curr Neuropharmacol. 2011 Dec;9(4):559-73. (PMID: 22654716)
      J Neurochem. 2009 Sep;110(5):1617-27. (PMID: 19575707)
      Eur J Pharmacol. 2012 Jan 15;674(2-3):104-11. (PMID: 22094065)
      Nat Rev Neurosci. 2013 Jun;14(6):401-16. (PMID: 23674053)
      J Biol Chem. 2004 Jan 9;279(2):1415-21. (PMID: 14578353)
      Pharmacol Rep. 2014 Aug;66(4):660-9. (PMID: 24948069)
      J Alzheimers Dis. 2009;16(3):585-99. (PMID: 19276553)
      Nat Med. 2003 May;9(5):589-95. (PMID: 12669033)
      Cytokine. 2006 Oct;36(1-2):1-8. (PMID: 17161612)
      Clin Immunol. 2014 Feb;150(2):153-60. (PMID: 24412909)
      J Neurosci. 2002 Feb 1;22(3):782-90. (PMID: 11826108)
      Neurotoxicology. 2011 Dec;32(6):683-92. (PMID: 21963524)
      J Neurochem. 2002 Jun;81(6):1285-97. (PMID: 12068076)
      Exp Hematol. 2010 Oct;38(10):860-7. (PMID: 20619313)
      Neurobiol Dis. 2010 Mar;37(3):510-8. (PMID: 19913097)
      J Neurosci. 2003 Jul 16;23(15):6181-7. (PMID: 12867501)
      Neuropsychiatr Dis Treat. 2014 Aug 16;10:1489-95. (PMID: 25170268)
      J Mol Neurosci. 2010 May;41(1):66-73. (PMID: 19685013)
      J Biol Chem. 2001 Nov 30;276(48):44527-33. (PMID: 11551948)
      Exp Neurol. 2001 Jun;169(2):219-30. (PMID: 11358437)
      Exp Neurol. 2007 Nov;208(1):1-25. (PMID: 17720159)
      J Neuroinflammation. 2015;12:34. (PMID: 25889069)
      J Pharmacol Exp Ther. 2000 May;293(2):607-17. (PMID: 10773035)
      Fundam Clin Pharmacol. 2008 Oct;22(5):453-64. (PMID: 18710400)
      Neurobiol Dis. 2000 Aug;7(4):429-47. (PMID: 10964613)
      Eur J Neurosci. 2000 Jul;12(7):2265-72. (PMID: 10947805)
      FASEB J. 1991 Sep;5(12):2652-60. (PMID: 1916089)
      Trends Immunol. 2002 Feb;23(2):89-96. (PMID: 11929132)
      J Neuroinflammation. 2012;9:197. (PMID: 22889165)
      J Pharmacol Exp Ther. 2000 Oct;295(1):125-32. (PMID: 10991969)
      Ann N Y Acad Sci. 2002 May;962:318-31. (PMID: 12076984)
      Nat Genet. 2003 Sep;35(1):76-83. (PMID: 12881722)
      Annu Rev Neurosci. 1999;22:219-40. (PMID: 10202538)
      J Biol Chem. 2001 Aug 10;276(32):30188-98. (PMID: 11402028)
      Neuron. 2009 Oct 15;64(1):110-22. (PMID: 19840553)
      J Neurosci. 2008 Jul 23;28(30):7687-98. (PMID: 18650345)
      Neurochem Int. 2014 Apr;69:35-40. (PMID: 24607701)
      Pharmacol Res. 2005 Aug;52(2):133-9. (PMID: 15967378)
      Neurobiol Aging. 2007 Jun;28(6):894-906. (PMID: 21887889)
      Neuropharmacology. 2015 Sep;96(Pt A):55-69. (PMID: 25446571)
      Br J Pharmacol. 2009 Mar;156(6):933-40. (PMID: 19298258)
      J Pharmacol Exp Ther. 2006 Oct;319(1):44-52. (PMID: 16807359)
      J Neurochem. 2010 Jan;112(2):434-43. (PMID: 19895668)
      J Neuroinflammation. 2008;5:37. (PMID: 18759972)
      Inflammopharmacology. 2013 Dec;21(6):421-5. (PMID: 23896940)
      Biochem Biophys Res Commun. 2012 Sep 14;426(1):112-5. (PMID: 22917537)
    • Contributed Indexing:
      Keywords: IL-10; LPS; Parkinson’s disease; astrocytes; dopaminergic neurons; microglia
    • الرقم المعرف:
      0 (Anti-Inflammatory Agents)
      0 (Lipopolysaccharides)
      130068-27-8 (Interleukin-10)
    • الموضوع:
      Date Created: 20160106 Date Completed: 20161025 Latest Revision: 20181113
    • الموضوع:
      20240628
    • الرقم المعرف:
      PMC4730272
    • الرقم المعرف:
      10.3390/ijms17010025
    • الرقم المعرف:
      26729090